Voltage-Gated Potassium Channel Kv1.3 as a Therapeutic Target for Pancreatic Ductal Adenocarcinoma
Li, W.; Wilson, G.; Bachmann, M.; Wang, J.; Mattarei, A.; Paradisi, C.; Edwards, M.; Szabo, I.; Gulbins, E.; Ahmad, S.; Patel, S.
Show abstract
The mitochondrial voltage-gated potassium channel, Kv1.3, has been emerged as an attractive oncologic target but its function in pancreas cancer (PDAC) is unknown. In this study we evaluated tissue expression of Kv1.3 in resected PDAC from 55 patients and tumor inhibition in orthotopic mouse models using the recently developed Kv1.3 inhibitors PCARBTP and PAPTP. Immunohistochemistry of 55 human PDAC specimens showed that all tumors expressed Kv1.3 with 60% of tumor specimens having high Kv1.3 expression. In pancreas tumor models (Pan02 cells injected into C57BL/6 mice), PCARBTP and PAPTP treatment resulted in tumor reductions of 87% and 70%, respectively. When combined with gemcitabine/abraxane, this increased to 95% and 80% without resultant organ toxicity. In vivo models indicated PCARBTP-mediated cell death occurred through the p38-MAPK pathway. In vitro-generated resistant clones to PCARBTP escaped cell death through upregulation of the anti-oxidant system as determined using SWATH-MS analysis. These data show Kv1.3 is highly expressed in resected human PDAC and the use of novel mitochondrial Kv1.3 inhibitors combined with cytotoxic chemotherapies might be novel, effective treatment for PDAC.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Osthole Suppresses Prostate Cancer Progression by Modulating PRLR and the JAK2/STAT3 Signaling Axis 95%
- Augmentation of extracellular ATP synergizes with chemotherapy in triple negative breast cancer 94%
- miR-100-5p downregulates mTOR to suppress the proliferation, migration and invasion of prostate cancer cells 94%
Similar papers in this journal
- A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment. 95%
- Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma 94%
- Reshaping the Landscape of Locoregional Treatments for Breast Cancer Liver Metastases: A novel, intratumoral, p21-targeted percutaneous therapy increases survival in BALB/c mice inoculated with 4T1 triple negative breast cancer cells in the liver. 94%
Similar papers in this journal
- Comparative Immune profiling in Pancreatic Ductal Adenocarcinoma Progression Among South African patients 95%
- PDAC-ANN: an artificial neural network to predict Pancreatic Ductal Adenocarcinoma based on gene expression 94%
- Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of Triple Negative Breast Cancer 93%
Similar papers in this journal
- Hereditary Pancreatitis Model by Blastocyst Complementation in Mouse 92%
- 1,4-dihydroxy Quininib Attenuates Growth of Colorectal Cancer Cells and Xenografts and Regulates the TIE-2 Signaling Pathway in Patient Tumours 92%
- Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.